Eos Focused Equity Management L.P. Cuts Stake in Bioverativ Inc (BIVV)
Eos Focused Equity Management L.P. decreased its position in shares of Bioverativ Inc (NASDAQ:BIVV) by 6.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 28,211 shares of the biotechnology company’s stock after selling 2,028 shares during the quarter. Bioverativ makes up 2.5% of Eos Focused Equity Management L.P.’s investment portfolio, making the stock its 20th largest position. Eos Focused Equity Management L.P.’s holdings in Bioverativ were worth $1,521,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of BIVV. Robeco Institutional Asset Management B.V. bought a new position in Bioverativ in the 4th quarter worth about $105,000. American Assets Investment Management LLC bought a new position in Bioverativ in the 4th quarter worth about $108,000. Advisors Asset Management Inc. bought a new position in Bioverativ in the 3rd quarter worth about $137,000. TCI Wealth Advisors Inc. bought a new position in Bioverativ in the 3rd quarter worth about $186,000. Finally, Ladenburg Thalmann Financial Services Inc. bought a new position in Bioverativ in the 3rd quarter worth about $190,000. Institutional investors own 95.14% of the company’s stock.
BIVV has been the subject of several analyst reports. Zacks Investment Research upgraded Bioverativ from a “hold” rating to a “buy” rating and set a $62.00 target price for the company in a research note on Monday, January 8th. Jefferies Group raised their target price on Bioverativ to $79.00 and gave the stock a “buy” rating in a research note on Thursday, January 18th. Deutsche Bank set a $53.00 target price on Bioverativ and gave the stock a “hold” rating in a research note on Monday, November 20th. Credit Suisse Group restated a “neutral” rating and issued a $65.00 target price on shares of Bioverativ in a research note on Thursday, January 18th. Finally, Raymond James Financial downgraded Bioverativ from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 23rd. Thirteen investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $63.15.
COPYRIGHT VIOLATION WARNING: “Eos Focused Equity Management L.P. Cuts Stake in Bioverativ Inc (BIVV)” was reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/eos-focused-equity-management-l-p-cuts-stake-in-bioverativ-inc-bivv/1859062.html.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.